192
Views
10
CrossRef citations to date
0
Altmetric
Review

The Impact of Chronic Kidney Disease on Peripheral Artery Disease and Peripheral Revascularization

ORCID Icon, , , , ORCID Icon, , , , , ORCID Icon, , , & show all
Pages 3749-3759 | Published online: 23 Jul 2021

References

  • Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney Int Suppl. 2013;91–111. doi:10.1038/kisup.2012.67
  • De Nicola L, Provenzano M, Chiodini P, et al. Independent role of underlying kidney disease on renal prognosis of patients with chronic kidney disease under nephrology care. PLoS One. 2015;10(5):e0127071. doi:10.1371/journal.pone.0127071
  • Provenzano M, Garofalo C, Chiodini P, et al. Role of proteinuria in clinical research: for each old-answer, a new key-question. Recent Prog Med. 2020;111(2):74–81.
  • Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165–180. doi:10.1016/S0140-6736(11)60178-5
  • Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. a collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79(12):1331–1340. doi:10.1038/ki.2010.550
  • Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514–525. doi:10.1016/S2213-8587(15)00040-6
  • Ballew SH, Matsushita K. Cardiovascular risk prediction in CKD. Semin Nephrol. 2018;38(3):208–216. doi:10.1016/j.semnephrol.2018.02.002
  • Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840– e878. doi:10.1161/CIR.0000000000000664
  • Provenzano M, Coppolino G, Faga T, et al. Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer. Rev Cardiovasc Med. 2019;20(4):209–220.
  • Pena MJ, Stenvinkel P, Kretzler M, et al. Strategies to improve monitoring disease progression, assessing cardiovascular risk, and defining prognostic biomarkers in chronic kidney disease. Kidney Int Suppl. 2017;7(2):107–113. doi:10.1016/j.kisu.2017.07.005
  • Hayatsu Y, Ruel M, Sun LY. Renal insufficiency and severe coronary artery disease: should coronary artery bypass grafting, off-pump coronary artery bypass grafting or percutaneous coronary intervention be performed? Curr Opin Cardiol. 2019;34(6):645–649. doi:10.1097/HCO.0000000000000687
  • Xie Y, Bowe B, Mokdad AH, et al. Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94(3):567–581. doi:10.1016/j.kint.2018.04.011
  • De Nicola L, Donfrancesco C, Minutolo R, et al. Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008–12 National Health Examination Survey. Nephrol Dial Transplant. 2015;30(5):806–814. doi:10.1093/ndt/gfu383
  • Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–663. doi:10.1001/archinte.164.6.659
  • Patel UD, Young EW, Ojo AO, et al. CKD progression and mortality among older patients with diabetes. Am J Kidney Dis. 2005;46(3):406–414. doi:10.1053/j.ajkd.2005.05.027
  • Van Zuilen AD, Van der Tweel I, Blankestijn PJ, et al. Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232]. Trials. 2006;7(1):8. doi:10.1186/1745-6215-7-8
  • Landray MJ, Thambyrajah J, McGlynn FJ, et al. Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis. 2001;38(3):537–546. doi:10.1053/ajkd.2001.26850
  • Norris K, Bourgoigne J, Gassman J, et al. Cardiovascular outcomes in the African American study of kidney disease and hypertension (AASK) trial. Am J Kidney Dis. 2006;48(5):739–751. doi:10.1053/j.ajkd.2006.08.004
  • Provenzano M, Chiodini P, Minutolo R, et al. Reclassification of chronic kidney disease patients for end-stage renal disease risk by proteinuria indexed to estimated glomerular filtration rate: multicentre prospective study in nephrology clinics. Nephrol Dial Transplant. 2020;35(1):138–147.
  • Thomas B, Matsushita K, Abate KH, et al. Global cardiovascular and renal outcomes of reduced GFR. J Am Soc Nephrol. 2017;28(7):2167–2179. doi:10.1681/ASN.2016050562
  • Theilade S, Lajer M, Jorsal A, et al. Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes. Diabet Med. 2012;29(8):990–994. doi:10.1111/j.1464-5491.2012.03633.x
  • Provenzano M, Coppolino G, De Nicola L, et al. Unraveling cardiovascular risk in renal patients: a new take on old tale. Front Cell Dev Biol. 2019;3(7):314. doi:10.3389/fcell.2019.00314
  • Gerhard-Herman MD, Gornik HL, Barrett C, et al. Guideline on the management of patients with lower extremity peripheral artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2017;135(12):e726–e779.
  • Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5–67.
  • Berger JS, Hochman J, Lobach I, et al. Modifiable risk factor burden and the prevalence of peripheral artery disease in different vascular territories. J Vasc Surg. 2013;58(3):673–81.e1. doi:10.1016/j.jvs.2013.01.053
  • Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National health and nutrition examination survey, 1999–2000. Circulation. 2004;110(6):738–743. doi:10.1161/01.CIR.0000137913.26087.F0
  • Creager MA. The crisis of vascular disease and the journey to vascular health: presidential address at the American Heart Association 2015 Scientific Sessions. Circulation. 2016;133(24):2593–2598. doi:10.1161/CIR.0000000000000434
  • O’Hare AM, Vittinghoff E, Hsia J, et al. Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the heart and estrogen/progestin replacement study (HERS). J Am Soc Nephrol. 2004;15(4):1046. doi:10.1097/01.ASN.0000119574.27772.FD
  • Wattanakit K, Folsom AR, Selvin E, et al. Kidney function and risk of peripheral arterial disease: results from the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2007;18(2):629. doi:10.1681/ASN.2005111204
  • Matsushita K, Ballew SH, Coresh J, et al. Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2017;5(9):718–728. doi:10.1016/S2213-8587(17)30183-3
  • Staplin N, Haynes R, Herrington WG, et al. Smoking and adverse outcomes in patients with CKD: the study of heart and renal protection (SHARP). Am J Kidney Dis. 2016;68(3):371–380. doi:10.1053/j.ajkd.2016.02.052
  • Ninomiya T, Perkovic V; Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ. 2013;347:f5680.
  • Jaar BG, Plantinga LC, Astor BC, et al. Novel and traditional cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients. Adv Chronic Kidney Dis. 2007;14(3):304–313. doi:10.1053/j.ackd.2007.04.005
  • Rajagopalan S, Dellegrottaglie S, Furniss AL, et al. Peripheral arterial disease in patients with end-stage renal disease: observations from the dialysis outcomes and practice patterns study (DOPPS). Circulation. 2006;114(18):1914–1922. doi:10.1161/CIRCULATIONAHA.105.607390
  • Bourrier M, Ferguson TW, Embil JM, et al. Peripheral artery disease: its adverse consequences with and without CKD. Am J Kidney Dis. 2020;75(5):705–712. doi:10.1053/j.ajkd.2019.08.028
  • Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018;137(4):338–350. doi:10.1161/CIRCULATIONAHA.117.032235
  • Hishida M, Menez S, Matsushita K. Peripheral artery disease in CKD: anatomically peripheral but clinically central. Am J Kidney Dis. 2020;75(5):687–689. doi:10.1053/j.ajkd.2019.10.006
  • Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517–538. doi:10.1016/S0741-5214(97)70045-4
  • Hardman RL, Jazaeri O, Yi J, et al. Overview of classification systems in peripheral artery disease. Semin Intervent Radiol. 2014;31:378–388.
  • Mills JL Sr, Conte MS, Armstrong DG, et al.; Society for Vascular Surgery Lower Extremity Guidelines Committee The society for vascular surgery lower extremity threatened limb classification system: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014;59(1):220–34.e1–2. doi:10.1016/j.jvs.2013.08.003.
  • Farchioni L, Gennai S, Giuliani E, et al. A prognostic risk score for major amputation in dialysis patients with chronic limb-threatening ischemia after endovascular revascularization. Int Angiol. 2021;40(3):206–212; PMID: 33660496. doi: 10.23736/S0392-9590.21.04523-5
  • Arinze NV, Gregory A, Francis JM, et al. Unique aspects of peripheral artery disease in patients with chronic kidney disease. Vasc Med. 2019;24(3):251–260. doi:10.1177/1358863X18824654
  • Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2017;135(12):e726–e779.
  • Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56(12):956–965. PMID: 20828648. doi:10.1016/j.jacc.2010.02.068
  • Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3):609S–626S. PMID: 15383487. doi:10.1378/chest.126.3_suppl.609S
  • Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–2192; PMID: 21663949; PMCID: PMC3145073. doi: 10.1016/S0140-6736(11)60739-3
  • De Nicola L, Provenzano M, Chiodini P, et al.; SIR-SIN study group. Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: multicenter prospective study in Italy. Nutr Metab Cardiovasc Dis. 2015; 25(8):756–762. doi:10.1016/j.numecd.2015.04.001. PMID: 26026213.
  • Mazari FA, Gulati S, Rahman MN, et al. Early outcomes from a randomized, controlled trial of supervised exercise, angioplasty, and combined therapy in intermittent claudication. Ann Vasc Surg. 2010;24(1):69–79. doi:10.1016/j.avsg.2009.07.005
  • Reilly MP, Mohler ER 3rd. Cilostazol: treatment of intermittent claudication. Ann Pharmacother. 2001;35(1):48–56.
  • Thompson PD, Zimet R, Forbes WP, et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90(12):1314–1319. doi:10.1016/S0002-9149(02)02869-2
  • Bracale UM, Giribono AM, Spinelli D, et al. Long-term results of endovascular treatment of TASC C and D aortoiliac occlusive disease with expanded polytetrafluoroethylene stent graft. Ann Vasc Surg. 2019;56:254–260. doi:10.1016/j.avsg.2018.07.060
  • Tendera M, Aboyans V; European Stroke Organisation. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the task force on the diagnosis and treatment of peripheral artery diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851–2906.
  • Ambur V, Park P, Gaughan JP, et al. The impact of chronic kidney disease on lower extremity bypass outcomes in patients with critical limb ischemia. J Vasc Surg. 2019;69(2):491–496. doi:10.1016/j.jvs.2018.05.229
  • Biancari F, Salenius JP, Heikkinen M, et al. Risk-scoring method for prediction of 30-day postoperative outcome after infrainguinal surgical revascularization for critical lower-limb ischemia: a Finnvasc registry study. World J Surg. 2007;31(1):217–25;discussion 226–7. doi:10.1007/s00268-006-0242-y
  • Schanzer A, Mega J, Meadows J, et al. Risk stratification in critical limb ischemia: derivation and validation of a model to predict amputation-free survival using multicenter surgical outcomes data. J Vasc Surg. 2008;48(6):1464–1471. doi:10.1016/j.jvs.2008.07.062
  • Farber A. Chronic limb-threatening ischemia. N Engl J Med. 2018;379(2):171–180. doi:10.1056/NEJMcp1709326
  • Leskinen Y, Salenius JP, Lehtimäk T, et al. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis. 2002;40(3):472–479. doi:10.1053/ajkd.2002.34885
  • United States Renal Data System. Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases;2018.
  • Owens CD, Ho KJ, Kim S, et al. Refinement of survival prediction in patients undergoing lower extremity bypass surgery: stratification by chronic kidney disease classification. J Vasc Surg. 2007;45(5):944–952. doi:10.1016/j.jvs.2007.01.025
  • Zlatanovi P, Koncar I, Dragas M, et al. Combined impact of chronic kidney disease and contrast induced acute kidney injury on long-term outcomes in patients with acute lower limb ischaemia. Eur J Vasc Endovasc Surg. 2018;56(1):78–86. doi:10.1016/j.ejvs.2018.03.008
  • Ortmann J, Gahl B, Diehm N, et al. Survival benefits of revascularization in patients with critical limb ischemia and renal insufficiency. J Vasc Surg. 2012;56(3):737–45.e1. doi:10.1016/j.jvs.2012.02.049
  • Kumada Y, Aoyama T, Ishii H, et al. Long-term outcome of percutaneous transluminal angioplasty in chronic haemodialysis patients with peripheral arterial disease. Nephrol Dial Transplant. 2008;23(12):3996–4001. doi:10.1093/ndt/gfn378
  • Graziani L, Silvestro A, Bertone V, et al. Percutaneous transluminal angioplasty is feasible and effective in patients on chronic dialysis with severe peripheral artery disease. Nephrol Dial Transplant. 2007;22(4):1144–1149. doi:10.1093/ndt/gfl764
  • O’Hare AM, Bertenthal D, Sidawy AN, et al. Renal insufficiency and use of revascularization among a national cohort of men with advanced lower extremity peripheral arterial disease. Clin J Am Soc Nephrol. 2006;1(2):297–304. doi:10.2215/CJN.01070905
  • Lüders F, Bunzemeier H, Engelbertz C, et al. CKD and acute and long-term outcome of patients with peripheral artery disease and critical limb ischemia. Clin J Am Soc Nephrol. 2016;11:216–222.
  • Kumada Y, Nogaki H, Ishii H, et al. Clinical outcome after infrapopliteal bypass surgery in chronic hemodialysis patients with critical limb ischemia. J Vasc Surg. 2015;61(2):400–404. doi:10.1016/j.jvs.2014.09.007
  • Patel VI, Mukhopadhyay S, Guest JM, et al. Impact of severe chronic kidney disease on outcomes of infrainguinal peripheral arterial intervention. J Vasc Surg. 2014;59(2):368–375. doi:10.1016/j.jvs.2013.09.006
  • Andreucci M, Faga T, Serra R, et al. Update on the renal toxicity of iodinated contrast drugs used in clinical medicine. Drug Healthc Patient Saf. 2017;22(4):25–37. doi:10.2147/DHPS.S122207
  • Andreucci M, Faga T, Pisani A, et al. Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors. ScientificWorldJournal. 2014;2014:823169. doi:10.1155/2014/823169
  • Andreucci M, Faga T, Pisani A, et al. Acute kidney injury by radiographic contrast media: pathogenesis and prevention. Biomed Res Int. 2014;2014:362725.
  • O’Hare AM, Feinglass J, Sidawy AN, et al. Impact of renal insufficiency on short-term morbidity and mortality after lower extremity revascularization: data from the department of veterans affairs’ national surgical quality improvement program. J Am Soc Nephrol. 2003;14(5):1287–1295. doi:10.1097/01.ASN.0000061776.60146.02
  • Provenzano M, De Nicola L, Pena MJ, et al. Precision nephrology is a non-negligible state of mind in clinical research: remember the past to face the future. Nephron. 2020;144(10):463–478. doi:10.1159/000508983
  • Andreucci M, Provenzano M, Faga T, et al. Aortic aneurysms, chronic kidney disease and metalloproteinases. Biomolecules. 2021;11(2):194. doi:10.3390/biom11020194
  • Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease. Blood Purif. 2015;39(1–3):84–92. doi:10.1159/000368940
  • Malhotra R, Katz R, Jotwani V, et al. Urine markers of kidney tubule cell injury and kidney function decline in SPRINT Trial participants with CKD. Clin J Am Soc Nephrol. 2020;15(3):349–358. doi:10.2215/CJN.02780319
  • Provenzano M, Rivoli L, Garofalo C, et al. Renal resistive index in chronic kidney disease patients: possible determinants and risk profile. PLoS One. 2020;15(4):e0230020. doi:10.1371/journal.pone.0230020
  • Gorriz JL, Molina P, Cervero´n MJ, et al. Vascular calcification in patients with non dialysis CKD over 3 years. Clin J Am Soc Nephrol. 2015;10(4):654–666. doi:10.2215/CJN.07450714
  • Perticone M, Maio R, Sciacqua A, et al. Serum phosphorus levels are associated with endothelial dysfunction in hypertensive patients. Nutr Metab Cardiovasc Dis. 2016;26(8):683–688. doi:10.1016/j.numecd.2016.02.003
  • Provenzano M, Andreucci M, Garofalo C, et al. The association of matrix metalloproteinases with chronic kidney disease and peripheral vascular disease: a light at the end of the tunnel? Biomolecules. 2020;10(1):154. doi:10.3390/biom10010154
  • Hu Y, Ivashkiv LB. Costimulation of chemokine receptor signaling by matrix metalloproteinase-9 mediates enhanced migration of IFN-alpha dendritic cells. J Immunol. 2006;176(10):6022–6033. doi:10.4049/jimmunol.176.10.6022
  • Li Q, Park PW, Wilson CL, et al. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell. 2002;111(5):635–646. doi:10.1016/S0092-8674(02)01079-6
  • Yamashita CM, Dolgonos L, Zemans RL, et al. Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Am J Pathol. 2011;179(4):1733–1745. doi:10.1016/j.ajpath.2011.06.041
  • Monaco C, Andreakos E, Kiriakidis S, et al. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA. 2004;101(15):5634–5639. doi:10.1073/pnas.0401060101
  • Sritharan K, Essex D, Sandison A, et al. Membrane Type-1 matrix metalloproteinase: a key player in carotid plaque instability and symptomatic carotid atherosclerotic disease. Br J Surg. 2008;95:2.
  • De Caridi G, Massara M, Spinelli F, et al. Matrix metalloproteinases and risk stratification in patients undergoing surgical revascularisation for critical limb ischaemia. Int Wound J. 2016;13(4):493–499. doi:10.1111/iwj.12464
  • Gondouin B, Cerini C, Dou L, et al. Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney Int. 2013;84(4):733–744. doi:10.1038/ki.2013.133
  • Yang K, Du C, Wang X, et al. Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease associated thrombosis in mice. Blood. 2017;129(19):2667–2679. doi:10.1182/blood-2016-10-744060
  • Provenzano M, Andreucci M, De Nicola L, et al. The role of prognostic and predictive biomarkers for assessing cardiovascular risk in chronic kidney disease patients. Biomed Res Int. 2020;2020:2314128. doi:10.1155/2020/2314128
  • Provenzano M, Rotundo S, Chiodini P, et al. Contribution of predictive and prognostic biomarkers to clinical research on chronic kidney disease. Int J Mol Sci. 2020;21(16):5846. doi:10.3390/ijms21165846
  • Liabeuf S, Lenglet A, Desjardins L, et al. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int. 2012;82(12):1297–1303. doi:10.1038/ki.2012.301
  • Nakano T, Ninomiya T, Sumiyoshi S, et al. Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study. Am J Kidney Dis. 2010;55(1):21–30. doi:10.1053/j.ajkd.2009.06.034
  • Heerspink HJL, Gansevoort RT. Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view. Clin J Am Soc Nephrol. 2015;10(6):1079–1088. doi:10.2215/CJN.11511114
  • De Zeeuw D, Heerspink HJL. Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy. Nephrol Dial Transplant. 2020;35(Supplement_2):ii38–ii42. doi:10.1093/ndt/gfaa013
  • Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10184):1937–1947.
  • Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229. doi:10.1056/NEJMoa2025845
  • Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi:10.1056/NEJMoa1811744
  • Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(4):323–334. doi:10.1056/NEJMoa1515920
  • Provenzano M, Andreucci M, Garofalo C, et al. Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease. Expert Opin Investig Drugs. 2021;30(3):253–262. doi:10.1080/13543784.2021.1869720
  • Garimella PS, Hirsch AT. Peripheral artery disease and chronic kidney disease: clinical synergy to improve outcomes. Adv Chronic Kidney Dis. 2014;21(6):460–471.